Daily close, T-120 (11/21/24) through T+5. Run-up high $7.53 on 3/13/25, low $3.67 on 1/6/25 (T-120 to T-1). FDA decision 5/8/25. Historical price action, not a forecast.
Positioning before the decision
On Apr 24, 2025, 14 days before the decision date, at-the-money options priced a move of ±11.2% through May 16, 2025 (the first listed expiry after the decision; ATM implied volatility 110%). The stock closed +3.7% at the first close across the decision and +6.6% five trading days on. A straddle priced weeks out covers ordinary movement plus the event, so this is the move the options market priced through that expiry, not the event-implied move alone. How this compares across 1,000+ decisions.
Decision facts
FDA decision date2025-05-08
DrugAVMAPKI FAKZYNJA CO-PACK
IndicationRecurrent low-grade serous ovarian cancer (LGSOC)
Yes. The FDA approved the application for AVMAPKI FAKZYNJA CO-PACK on May 8, 2025. The primary source is linked on this page.
What was AVMAPKI FAKZYNJA CO-PACK under FDA review for?
The application covered Recurrent low-grade serous ovarian cancer (LGSOC). The FDA approved the application on May 8, 2025.
How did VSTM stock react to the FDA decision?
On the decision day VSTM moved +3.7%. That is the recorded reaction to this specific event -- historical measurement, not a prediction, and not investment advice.